AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 165 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $276,000 | -16.4% | 6,000 | 0.0% | 0.02% | -15.4% |
| Q2 2021 | $330,000 | +6.8% | 6,000 | 0.0% | 0.03% | 0.0% |
| Q1 2021 | $309,000 | +34.9% | 6,000 | +76.5% | 0.03% | +4.0% |
| Q1 2019 | $229,000 | -12.6% | 3,400 | 0.0% | 0.02% | -13.8% |
| Q3 2018 | $262,000 | -8.4% | 3,400 | 0.0% | 0.03% | -14.7% |
| Q2 2018 | $286,000 | +2.9% | 3,400 | 0.0% | 0.03% | -2.9% |
| Q1 2018 | $278,000 | +22.5% | 3,400 | 0.0% | 0.04% | +20.7% |
| Q3 2017 | $227,000 | +2.7% | 3,400 | 0.0% | 0.03% | -21.6% |
| Q4 2015 | $221,000 | -7.9% | 3,400 | 0.0% | 0.04% | -9.8% |
| Q3 2015 | $240,000 | -36.5% | 3,400 | 0.0% | 0.04% | -25.5% |
| Q2 2015 | $378,000 | +17.8% | 3,400 | 0.0% | 0.06% | +19.6% |
| Q1 2015 | $321,000 | -22.7% | 3,400 | -8.1% | 0.05% | -23.3% |
| Q4 2014 | $415,000 | +35.2% | 3,700 | -26.0% | 0.06% | +27.7% |
| Q3 2014 | $307,000 | +34.1% | 5,000 | 0.0% | 0.05% | +46.9% |
| Q2 2014 | $229,000 | – | 5,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |